Structure Therapeutics is trading 4.07% down now at $45.44, with no new company-specific announcement or clinical, regulatory, earnings, or analyst catalyst identified for August 31, 2026.
- The stock fell from the August 28 close of $47.37.
- The decline comes amid a modestly weaker U.S. equity market and broader risk-off concerns tied to geopolitical tensions, oil prices, and interest-rate uncertainty.
- Those factors do not fully explain the outsized move.